Publication Month: Feb 2019 | Report Code: TIPRE00003016 | No. of Pages: 146 | Category: Medical Device | Status: Published
Gastric balloons are being preferred for weight loss during recent days. Unlike other procedures for weight loss, the gastric balloons are non-invasive methods for managing weight loss. The gastric balloon is placed through the mouth and is pushed down the esophagus, while it is in its least dilated form. Once the balloon reaches the stomach, it is filled with the saline or gas with the help of a tube, which is removed out once the balloon has been placed. These balloons are inserted in the stomach for around 6 months in order to obtain proper weight loss. The growth of the Gastric Balloon in healthcare market is attributed to the rising preference for minimally invasive methods for weight loss are the key driving factors for the growth of the market in the forecast period. However, the growth of the market is restrained by factors such as, lack of reimbursement and the side effects or complications caused due to the use of gastric balloons.
The Gastric Balloon in healthcare market is expected to witness substantial growth post-pandemic. The COVID-19 has affected economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. The COVID-19 crisis has overburdened public health systems in many countries and highlighted the strong need for sustainable investment in health systems. As the COVID-19 pandemic progresses, the healthcare industry is expected to see a drop in growth. The life sciences segment thrives due to increased demand for invitro diagnostic products and rising research and development activities worldwide. However, the medical technologies and imaging segment is witnessing drop in sales due to a smaller number of surgeries being carried out and delayed or prolonged equipment procurement. Additionally, virtual consultations by healthcare professionals are expected to become the mainstream care delivery model post-pandemic. With telehealth transforming care delivery, digital health will continue to thrive in coming years. In addition, disrupted clinical trials and the subsequent delay in drug launches is also expected to pave the way for entirely virtual trials in the future. New technologies such as mRNA is expected to emerge and shift the pharmaceutical industry and market is also expected to witness more vertical integration and joint ventures in coming years.
Get more information on this report :
Obesity rates have been increasing rapidly across the globe at a rapid rate. Overweight and obesity are defined as abnormal or excessive fat accumulation that presents a risk to health. Obesity is a medical condition in which excess body fat has been accumulated in the body and can be a leading factor for various other medical conditions. People are generally considered obese when their body mass index (BMI) is above 30 kg/m2. Factors such as, excessive food intake, lack of physical activity, and genetic susceptibility are considered to be the major contributors towards the rise in cases of obesity. A few cases are caused due to genes, endocrine disorders, medications, or mental disorder.
Obesity has been spreading at an epidemic rate during the recent years, specifically in the urban areas of the developed nations. As per estimates made by the WHO, during 2016, more than 1.9 billion adults, aged 18 years and older, were overweight. Of these over 650 million were obse. Also, an estimated 41 million children under the age of 5 years were overweight or obese. The prevalence of overweight and obesity among children and adolescents aged 5-19 has witnessed a dramatic from a minimal 4% in 1975 to above 18% in 2016. At present, obesity rates are significantly high in the United States, Mexico, New Zealand and Hungary, while they are lowest in Japan and Korea. Whereas, during the future years, obesity rates in countries such as Korea and Switzerland are anticipated to increase at the fastest rate.
Gastric balloons are implanted into the body through endoscopy and offers a weight loss upto 7 to 8 pounds. The Orbera gastric balloon offers a weight loss of 7 pounds on average. Whereas, the Obalon gastric balloon offers an average of 7.4 pounds or 3.42 percent of their total body weight. The benefits offered by gastric balloon along with prevalence of obesity worldwide is anticipated to fuel the growth of the gastric balloons market during the forecast period.
Minimally invasive surgeries are being performed widely during the recent years. There has been a rise in the number of people opting for minimally invasive surgeries. Unlike traditional surgical procedures, a minimally invasive surgery requires only a small incision to be made. Since these incisions are tiny, the patient recovers at a faster rate comparatively, with less discomfort. Some of the benefits of a minimally invasive surgery include, few small cuts, less trauma to the muscles, nerves and tissues, less bleeding & scarring, less trauma to organs, less pain and reduced use of narcotics, less hospital time, and less effect on the immune system.
The endoscopic intragastric balloon treatment is a non-surgical method to help lose weight in patients who suffer from obesity or morbid obesity. It is an endoscopic procedure, in which a balloon is inserted in the stomach, which occupies about half of the stomach’s space. The balloon remains in the stomach for a maximum of six months and it is meant to increase the feeling of satiety and limit food intake.
Since it does not require surgery, the procedure is conducted in an out-patient setting. Another main advantage is that the device helps avoid the risks associated with a surgical procedure and patients may be more comfortable with a non-surgical and non-pharmacological approach.
Endoscopy offers ease in the placement as well as the removal of a gastric balloon, along with limited complications due to the non-surgical nature of the procedure. Also, the absence of incisions unlike other weight loss surgeries is expected to fuel the growth of the market in the future years.
In terms of product, the Gastric Balloon in healthcare market is segmented into single gastric balloons, dual gastric balloons and triple gastric balloons. In 2018, the single gastric balloon segment held a largest market share of 89.0% of the gastric balloon market, by product.
Get more information on this report :
Based on filling material, the Gastric Balloon in healthcare market is segmented into saline filled and gas filled. In 2018, the saline filled segment held a largest market share of 91.5% of the gastric balloon market, by filling material.
In terms of end user, the Gastric Balloon in healthcare market is segmented into bariatric surgeons, gastrointestinal endoscopists, nutritionists, aesthetic practitioners, and other end users. In 2018, the bariatric surgeons segment held a largest market share of 47.4% of the gastric balloons market, by end user.
|Market Size Value in||US$ 67.3 Million in 2018|
|Market Size Value by||US$ 152.1 Million by 2027|
|Growth rate||CAGR of 9.7% from 2019-2027|
|No. of Pages||146|
|No. of Tables||77|
|No. of Charts & Figures||61|
|Historical data available||Yes|
|Segments covered||Product , Filling Material , End User , and Geography|
|Regional scope||North America, Europe, Asia Pacific, Middle East & Africa, South & Central America|
|Country scope||US, Canada, Mexico, UK, Germany, Spain, Italy, France, India, China, Japan, South Korea, Australia, UAE, Saudi Arabia, South Africa, Brazil, Argentina|
|Report coverage||Revenue forecast, company ranking, competitive landscape, growth factors, and trends|
|Free Sample Copy Available|
The Gastric Balloon in healthcare market players are adopting the product launch and expansion strategies to cater to changing customer demands worldwide, which also allows them to maintain their brand name globally.
o Elipse Gastric Balloons
o Orbera Gastric Balloons
o Other Single Gastric
The List of Companies - Gastric Balloon Market